Evotec maintains its own monoclonal antibody (mAb) research unit. Its growing discovery footprint is based on hybridoma technology leveraged to generate therapeutic mAb candidates. The unit deploys a breadth of workflows for immunisation, hybridoma generation and screening for binding and functional activity.
Protein production is a GLP-trained team able to produce mAbs in a short time and a wide range, from small scale (100 mg) to large-scale production (40 g), from hybridoma culture, transient transfection, or stable cell line culture after mAb gene synthesis and cloning. Volumes of culture are adapted to amount, from a few milliliters or liters (expression test, feasibility studies, and small-scale production) up to 100 liters (large-scale production).
Antibody purification is performed in two steps (affinity and polishing) to reach an optimal yield and high quality level, with high purity (≥ 99%), and low Endotoxin content for pre-clinical studies.